Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Massey IIT Research Operations
CONTACT
Massey CTO GU Team
CONTACT
Lead
Virginia Commonwealth University
With
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer with poor outcome and limited therapeutic options. Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate (ADC) directed against TROP2. The purpose of this study is to investigate the efficacy and safety of Sacituzumab Tirumotecan in patients with de novo or treatment related NEPC who progress after treatment with platinum-based chemotherapy.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted